Polymorphonuclear neutrophils from JAK2(V617F) positive MPD patients do not support hypercoagulability: A study with calibrated automated thrombography (CAT).
暂无分享,去创建一个
P. Feugier | T. Lecompte | C. Vigneron | D. Ranta | J. Perrin | F. Empereur
[1] H. Coenraad Hemker,et al. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.
[2] H. Hemker,et al. Phenotyping the haemostatic system by thrombography--potential for the estimation of thrombotic risk. , 2004, Thrombosis research.
[3] T. Lecompte,et al. In vitro effects of human neutrophil cathepsin G on thrombin generation: Both acceleration and decreased potential , 2010, Thrombosis and Haemostasis.
[4] F. Rosendaal,et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence , 2007, British journal of haematology.
[5] J. García‐Pagán,et al. Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera , 2004, British journal of haematology.
[6] T. Baglin,et al. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition , 2004, Journal of thrombosis and haemostasis : JTH.
[7] P. Petrides,et al. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. , 2006, Blood cells, molecules & diseases.
[8] T. Barbui,et al. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. , 2007, Haematologica.
[9] M. Cazzola,et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.
[10] T. Barbui,et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. , 2000, Blood.
[11] M. Marchand-Arvier,et al. Influence of polymorphonuclear leukocytes on the plasma clot formation as evaluated by thromboelastometry (ROTEM). , 2008, Thrombosis research.
[12] T. Barbui,et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. , 2007, Blood.
[13] A. Falanga,et al. Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders , 2007, Pathophysiology of Haemostasis and Thrombosis.
[14] S. Béguin,et al. Calibrated Automated Thrombin Generation in Frozen-Thawed Platelet-Rich Plasma to Detect Hypercoagulability , 2003, Pathophysiology of Haemostasis and Thrombosis.
[15] C. Burgaleta,et al. Increased CD11/CD18 Expression and Altered Metabolic Activity on Polymorphonuclear Leukocytes from Patients with Polycythemia vera and Essential Thrombocythemia , 2002, Acta Haematologica.
[16] M. Lishner,et al. Leukocyte function in chronic myeloproliferative disorders. , 1998, Blood cells, molecules & diseases.
[17] T. Barbui,et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments , 2008, Haematologica.
[18] T. Barbui,et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Ewton,et al. Essential thrombocythemia: a review of diagnostic and pathologic features. , 2006, Archives of pathology & laboratory medicine.
[20] T. Barbui,et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera , 2000 .
[21] V. Ugo,et al. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. , 2010, Thrombosis research.
[22] M. Trossaërt,et al. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype , 2008, Journal of thrombosis and haemostasis : JTH.
[23] K. M. Fazili,et al. Plant protease inhibitors: a defense strategy in plants , 2007 .
[24] S. Béguin,et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.
[25] D. Caramazza,et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms , 2009, Annals of Hematology.
[26] F. Cervantes,et al. Blood cell activation in myeloproliferative neoplasms , 2009, Haematologica.
[27] D. Larson,et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. , 2006, Mayo Clinic proceedings.
[28] A. Falanga,et al. Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed? , 2009, Thrombosis and Haemostasis.
[29] P. Giesen,et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. , 2003, Haematologica.
[30] T. Barbui,et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. , 2008, Blood.
[31] T. Barbui,et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. , 2007, Experimental hematology.
[32] J. Samuelsson,et al. Further studies of the defective stimulus‐response coupling for the oxidative burst in neutrophils in polycythemia vera , 1991, European journal of haematology.